David Nierengarten
Stock Analyst at Wedbush
(4.38)
# 369
Out of 5,124 analysts
212
Total ratings
51.45%
Success rate
18.61%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GBIO Generation Bio Co. | Upgrades: Outperform | $7 → $5.5 | $5.68 | -3.17% | 10 | Dec 16, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Reiterates: Outperform | $25 | $12.52 | +99.68% | 3 | Dec 11, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $20 | $8.18 | +144.50% | 8 | Dec 8, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $880 → $1,000 | $840.95 | +18.91% | 23 | Nov 14, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $9 → $7 | $8.99 | -22.14% | 11 | Nov 7, 2025 | |
| FATE Fate Therapeutics | Upgrades: Outperform | $5 → $7 | $0.98 | +612.40% | 16 | Oct 27, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $90 → $110 | $79.41 | +38.52% | 4 | Oct 17, 2025 | |
| ANAB AnaptysBio | Maintains: Outperform | $45 → $70 | $48.48 | +44.39% | 14 | Oct 15, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $38 → $44 | $41.25 | +6.67% | 4 | Oct 13, 2025 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $6 | $8.96 | -33.04% | 11 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $115 | $100.59 | +14.33% | 6 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4 | $3.65 | +9.59% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $15.31 | +69.82% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $7.49 | +193.72% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $13.08 | -38.84% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.75 | +300.00% | 4 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $27 | $12.93 | +108.82% | 8 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $21.48 | +53.63% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $11.57 | +72.86% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $16.83 | +84.19% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $75.48 | +19.24% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $44.05 | +6.70% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $30.31 | +31.97% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $32.76 | +37.36% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.00 | +900.00% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $4.29 | +319.58% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $35.52 | -71.85% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.47 | +245.82% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $27.72 | +105.63% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $175 | $28.93 | +504.91% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $2.75 | +18,081.82% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $7.36 | +715.22% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $7.70 | +146.75% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $23.00 | +226.09% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.20 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.93 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.55 | - | 3 | Nov 20, 2017 |
Generation Bio Co.
Dec 16, 2025
Upgrades: Outperform
Price Target: $7 → $5.5
Current: $5.68
Upside: -3.17%
BridgeBio Oncology Therapeutics
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $12.52
Upside: +99.68%
ORIC Pharmaceuticals
Dec 8, 2025
Reiterates: Outperform
Price Target: $20
Current: $8.18
Upside: +144.50%
argenx SE
Nov 14, 2025
Maintains: Outperform
Price Target: $880 → $1,000
Current: $840.95
Upside: +18.91%
Intellia Therapeutics
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $8.99
Upside: -22.14%
Fate Therapeutics
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $0.98
Upside: +612.40%
Disc Medicine
Oct 17, 2025
Maintains: Outperform
Price Target: $90 → $110
Current: $79.41
Upside: +38.52%
AnaptysBio
Oct 15, 2025
Maintains: Outperform
Price Target: $45 → $70
Current: $48.48
Upside: +44.39%
Kiniksa Pharmaceuticals International,
Oct 13, 2025
Maintains: Outperform
Price Target: $38 → $44
Current: $41.25
Upside: +6.67%
Nuvation Bio
Oct 13, 2025
Reiterates: Outperform
Price Target: $6
Current: $8.96
Upside: -33.04%
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $100.59
Upside: +14.33%
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $3.65
Upside: +9.59%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $15.31
Upside: +69.82%
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $7.49
Upside: +193.72%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $13.08
Upside: -38.84%
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $2.75
Upside: +300.00%
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $12.93
Upside: +108.82%
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $21.48
Upside: +53.63%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $11.57
Upside: +72.86%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $16.83
Upside: +84.19%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $75.48
Upside: +19.24%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $44.05
Upside: +6.70%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $30.31
Upside: +31.97%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $32.76
Upside: +37.36%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.00
Upside: +900.00%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $4.29
Upside: +319.58%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $35.52
Upside: -71.85%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.47
Upside: +245.82%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $27.72
Upside: +105.63%
Feb 29, 2024
Upgrades: Outperform
Price Target: $50 → $175
Current: $28.93
Upside: +504.91%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $2.75
Upside: +18,081.82%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $7.36
Upside: +715.22%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $7.70
Upside: +146.75%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $23.00
Upside: +226.09%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.20
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.93
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $9.55
Upside: -